Connor, Clark & Lunn Investment Management (CC&L)
ESPR

Connor, Clark & Lunn Investment Management (CC&L)’s Esperion Therapeutics ESPR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-822,618
Closed -$1.18M – 1550
2025
Q1 		$1.18M Sell
822,618
-109,390
-12% -$202K 0.01% 891
2024
Q4 		$2.05M Buy
932,008
+220,730
+31% +$515K 0.01% 718
2024
Q3 		$1.17M Buy
711,278
+295,378
+71% +$596K 0.01% 831
2024
Q2 		$923K Buy
+415,900
New +$978K ﹤0.01% 867
2024
Q1 		– Sell
-352,054
Closed -$1.05M – 1569
2023
Q4 		$1.05M Sell
352,054
-61,650
-15% -$80K ﹤0.01% 849
2023
Q3 		$405K Buy
413,704
+225,767
+120% +$327K ﹤0.01% 1075
2023
Q2 		$261K Sell
187,937
-51,602
-22% -$72.1K ﹤0.01% 1139
2023
Q1 		$381K Sell
239,539
-44,007
-16% -$227K ﹤0.01% 959
2022
Q4 		$1.77M Buy
283,546
+132,042
+87% +$944K 0.01% 571
2022
Q3 		$1.01M Buy
+151,504
New +$1.04M 0.01% 652
2019
Q4 		– Sell
-22,262
Closed -$816K – 975
2019
Q3 		$816K Buy
22,262
+9,125
+69% +$361K 0.01% 579
2019
Q2 		$611K Sell
13,137
-31,088
-70% -$1.46M ﹤0.01% 681
2019
Q1 		$1.78M Buy
44,225
+1,825
+4% +$81.9K 0.01% 435
2018
Q4 		$1.95M Buy
42,400
+950
+2% +$45.8K 0.01% 423
2018
Q3 		$1.84M Sell
41,450
-15,875
-28% -$729K 0.01% 448
2018
Q2 		$2.25M Buy
+57,325
New +$2.9M 0.01% 450
2015
Q2 		– Sell
-6,500
Closed -$602K – 627
2015
Q1 		$602K Buy
+6,500
New +$419K 0.01% 375

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ESPR Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 822,618 shares — an estimated $1.18M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ESPR in Q1 2015 and held it in 17 quarters. The position peaked at $2.25M in Q2 2018. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 822,618 Esperion Therapeutics shares in Q2 2025, an estimated $1.18M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Esperion Therapeutics in Q1 2015 and held it in 17 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Esperion Therapeutics position peaked at $2.25M in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.